Esomeprazole Magnesium; Naproxen Patent Expiration
Esomeprazole Magnesium; Naproxen is Used for relieving symptoms of arthritis and reducing the risk of NSAID-associated gastric ulcers. It was first introduced by Horizon Medicines Llc
Esomeprazole Magnesium; Naproxen Patents
Given below is the list of patents protecting Esomeprazole Magnesium; Naproxen, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Vimovo | US8945621 | Method for treating a patient at risk for developing an NSAID-associated ulcer | Oct 17, 2031 | Horizon |
Vimovo | US9220698 | Method for delivering a pharmaceutical composition to patient in need thereof | Mar 10, 2031 | Horizon |
Vimovo | US9393208 | Method for delivering a pharmaceutical composition to patient in need thereof | Sep 03, 2029 | Horizon |
Vimovo | US6926907 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb 28, 2023
(Expired) | Horizon |
Vimovo | US8557285 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
Vimovo | US8852636 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
Vimovo | US8858996 | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
May 31, 2022
(Expired) | Horizon |
Vimovo | US9161920 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
Vimovo | US9198888 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
Vimovo | US9345695 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
Vimovo | US9707181 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
Vimovo |
US6369085 (Pediatric) | Form of S-omeprazole |
Nov 25, 2018
(Expired) | Horizon |
Vimovo |
US7411070 (Pediatric) | Form of S-omeprazole |
Nov 25, 2018
(Expired) | Horizon |
Vimovo | US7745466 | Form of S-omeprazole |
Oct 13, 2018
(Expired) | Horizon |
Vimovo | US6369085 | Form of S-omeprazole |
May 25, 2018
(Expired) | Horizon |
Vimovo | US7411070 | Form of S-omeprazole |
May 25, 2018
(Expired) | Horizon |
Vimovo |
US5900424 (Pediatric) | Omeprazole magnesium salt form |
Nov 04, 2016
(Expired) | Horizon |
Vimovo | US5900424 | Omeprazole magnesium salt form |
May 04, 2016
(Expired) | Horizon |
Vimovo |
US5714504 (Pediatric) | Compositions |
Aug 03, 2015
(Expired) | Horizon |
Vimovo | US5714504 | Compositions |
Feb 03, 2015
(Expired) | Horizon |
Vimovo |
US6875872 (Pediatric) | Compounds |
Nov 27, 2014
(Expired) | Horizon |
Vimovo | US6875872 | Compounds |
May 27, 2014
(Expired) | Horizon |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Esomeprazole Magnesium; Naproxen's patents.
Latest Legal Activities on Esomeprazole Magnesium; Naproxen's Patents
Given below is the list recent legal activities going on the following patents of Esomeprazole Magnesium; Naproxen.
Activity | Date | Patent Number |
---|---|---|
![]() | ||
Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jan, 2024 | US9393208 |
Expire Patent Critical
| 08 Jan, 2024 | US9198888 |
Expire Patent Critical
| 27 Nov, 2023 | US9161920 |
Maintenance Fee Reminder Mailed Critical
| 24 Jul, 2023 | US9198888 |
Payment of Maintenance Fee, 8th Year, Large Entity | 29 Jun, 2023 | US9220698(Litigated) |
Maintenance Fee Reminder Mailed Critical
| 12 Jun, 2023 | US9161920 |
Expire Patent Critical
| 21 Nov, 2022 | US8858996 |
Payment of Maintenance Fee, 8th Year, Large Entity | 03 Aug, 2022 | US8945621(Litigated) |
Expire Patent Critical
| 01 Aug, 2022 | US7745466(Litigated) |
Maintenance Fee Reminder Mailed Critical
| 06 Jun, 2022 | US8858996 |
Esomeprazole Magnesium; Naproxen's Family Patents
